[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647444":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":39,"locations":10,"responsibleParty":48,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":10},{"fullName":5,"class":6},"Centre Hospitalier Universitaire Vaudois","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients With Suspected VEXAS Syndrome",null,"Adults older than 50 years admitted to participating Internal Medicine departments with otherwise unexplained systemic inflammation and hematologic abnormalities, including fever, elevated inflammatory markers, macrocytic anemia, thrombocytopenia, or other cytopenias. Participants will be assessed using routinely available clinical, laboratory, and imaging data. Patients meeting the predefined criteria for suspected VEXAS syndrome will undergo molecular testing for UBA1 mutations",[13],"Diagnostic Test: UBA1 Genetic Testing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","UBA1 Genetic Testing","Blood or bone marrow samples from participants with clinical features suggestive of VEXAS syndrome will be analyzed for somatic mutations in the UBA1 gene. Molecular testing will be performed centrally at the Immunology Laboratory of IRCCS Burlo Garofolo in Trieste.",[9],[21],"Molecular confirmation of VEXAS syndrome",[23,27,31,34,37],{"name":24,"affiliation":25,"role":26},"Giacomo Emmi, MD, PhD","CHUV Service d'immunologie et allergie, Lausanne, Switzerland","PRINCIPAL_INVESTIGATOR",{"name":28,"affiliation":29,"role":30},"Francesco Zaja","University of Trieste","STUDY_CHAIR",{"name":32,"affiliation":33,"role":30},"Fabio Fiammengo","FADOI-Friuli Venezia Giulia Network)",{"name":35,"affiliation":36,"role":30},"Alberto Tommasini","IRCCS Burlo Garofolo",{"name":38,"affiliation":29,"role":30},"Maria Letizia Urban",[40,44],{"name":24,"role":41,"phone":42,"phoneExt":10,"email":43},"CONTACT","+393286852815","giacomo.emmi@chuv.ch",{"name":45,"role":41,"phone":46,"phoneExt":10,"email":47},"Maria Letizia Urban, MD, PhD","+393478732241","marialetizia.urban@units.it",{"type":26,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Giacomo Emmi","Professor",[52,53],{"name":36,"class":6},{"name":33,"class":54},"UNKNOWN","100647444","clinical-phenotype-and-prevalence-of-vexas-syndrome-in-internal-medicine-100647444",false,"NCT07708688","Clinical Phenotype and Prevalence of VEXAS Syndrome in Internal Medicine","FIND-VEXAS Project (Friuli Internal Medicine Network for Detection of VEXAS Syndrome): Clinical Phenotype and Prevalence of VEXAS Syndrome in Internal Medicine","FIND-VEXAS","Inclusion Criteria:\n\n* Age older than 50 years.\n* Admission to a participating Internal Medicine department within the FADOI Friuli Venezia Giulia network.\n* Presence of otherwise unexplained systemic inflammation and\u002For hematologic abnormalities.\n* At least one of the following clinical or laboratory findings:\n* unexplained fever;\n* elevated C-reactive protein and\u002For erythrocyte sedimentation rate;\n* macrocytic anemia;\n* thrombocytopenia or other cytopenias;\n* systemic inflammatory manifestations without a clearly identified cause.\n* Availability of clinical, laboratory, and imaging data required for assessment according to the study screening pathway.\n* Provision of informed consent, where required by the approved study protocol and applicable regulations.\n\nExclusion Criteria:\n\n* Systemic inflammation adequately explained by an active infection.\n* Systemic inflammation adequately explained by a solid malignancy.\n* Clinical or laboratory abnormalities with another clearly established etiology.\n* Insufficient clinical or laboratory information to assess eligibility according to the study screening pathway.\n* Inability or refusal to provide informed consent, where consent is required.","ALL","50 Years",{"count":66,"type":67},50,"ESTIMATED","OBSERVATIONAL","The FIND-VEXAS project is a multicenter, cross-sectional observational study conducted in Internal Medicine departments in the Friuli Venezia Giulia region of Italy.\n\nThe study aims to estimate how frequently VEXAS syndrome occurs among adults older than 50 years who are admitted to Internal Medicine units with otherwise unexplained systemic inflammation or hematologic abnormalities, such as fever, elevated inflammatory markers, macrocytic anemia, thrombocytopenia, or other cytopenias.\n\nParticipants will be assessed using clinical information, physical examination findings, routine laboratory tests, and imaging data. Patients with findings suggestive of VEXAS syndrome will be selected for confirmatory genetic testing of the UBA1 gene using blood or bone marrow samples.\n\nIn addition to estimating the prevalence of genetically confirmed VEXAS syndrome, the study will describe the clinical manifestations, hematologic abnormalities, inflammatory profile, and organ involvement of patients with suspected or confirmed disease.",[71],"Vexas Syndrome",[73,74,75,76,77],"VEXAS Syndrome","UBA1 Mutation","Systemic Inflammation","Prevalence","incidence","NOT_YET_RECRUITING","2026-07-13",{"date":81,"type":82},"2026-07-16","ACTUAL",{"date":84,"type":67},"2026-07",{"date":86,"type":67},"2028-06",{"name":5,"class":6}]